Golden
Cellerant Therapeutics

Cellerant Therapeutics

A biotechnology company that develops treatments for cancer and hematologic conditions

Cellerant Therapeutics is a clinical stage biotechnology company based in San Carlos, California that develops cell- and antibody-based immunotherapies for hematological malignancies and other blood-related disorders. Cellerant's pipeline includes Romyelocel-L (CLT-008) and two antibody drug conjugates (ADC), CLT030 and CSC012-ADC. 



Romyelocel-L is an off-the-shelf universal cell therapy intended to prevent infections during neutropenia, a severe side effect of many chemotherapy regimens, particularly for acute myeloid leukemia (AML) and other blood related disorders. It has the potential to significantly reduce the risk of serious infection. Romyelocel-L is manufactured from hematopoietic stem cells obtained from screened and tested healthy donors. The stem cells are then expanded and differentiated into myeloid progenitor cells (MPCs) and is then cryopreserved. The FDA has granted Romyelocel-L Regenerative Medicine Advance Therapy (RMAT) designation for the prevention of neutropenia in AML. Cellerant plans to launch Phase 3 trials in 2019. The therapy is also being tested for efficacy to treat neutropenia in acute radiation syndrome (ARS) and increase tolerance of organ transplants.



CLT030, which is in development and is expected to enter Phase 1 clinical trials in 2019, is an ADC with a highly potent, DNA-binding payload, for the treatment of AML. It targets C-type lectin molecules (CLEC12A), a cell surface marker highly expressed on leukemic stem cells. It has shown promising efficacy in animal models.



CSC012 is a lead Interleukin-1 receptor accessory protein (IL1RAP) targeting antibody that has been selected and conjugated with a series of linker payloads to generate the antibody drug conjugate, CSC012-ADC. In vitro and in vivo results have demonstrated that it is a potent ADC and an excellent candidate for further development as a targeted treatment for AML.

Timeline

People

Name
Role
Related Golden topics

Angelica Rusan

Employee



Antoun Nabhan

Investor



Daphne Fong

Employee



Eric Morse

Employee



Esther Danenberg

Employee



Gautam Banik

VP Manufacturing & Process Sciences



Gautam Banik

Employee



Irving L. Weissman

Founder



Jagath Reddy Junutula

VP Antibody Discovery & Development



Ram Mandalam

President & CEO



Rodney Young

CFO



Sean Givens

Employee



Sean Healy

Employee



Timothy C. Fong

Employee



Vanessa Love Van Pell

Employee



William Reed

Employee



Further reading

Title
Author
Link
Type
Date

Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for Romyelocel-L to Prevent Infections During Neutropenia

Business Wire

Web



Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy

Business Wire

Web



Documentaries, videos and podcasts

Title
Date
Link

Cellerant Therapeutics

October 18, 2018

Companies

Company
CEO
Location
Products/Services









References